Fundraising Fox
/Companies
Sign in

Phenomic AI

Toronto, CA · Founded 2017 · 14 employees on LinkedIn · 9 known investors

Find your way into Phenomic AI

Sign up to see every warm intro you have to Phenomic AI

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Phenomic AI team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Phenomic AI is a biotech company developing therapies for solid tumors using a machine-learning-powered transcriptomics platform that analyzes single-cell RNA data to identify drug targets and understand tumor biology. The company develops antibody-based therapies informed by its analysis of cell-cell interactions in tumor microenvironments, with current programs targeting stromal and immune components of difficult-to-treat cancers.

AI & Machine LearningBiotechDeep Tech

Founders & leadership

Phenomic AI was founded in 2017 by Sam Cooper and Oren Kraus.

SCSam Cooper
Sam CooperCo-founder & CTOSam Cooper holds a PhD in Computational Medicine from Imperial College London, where he studied cancer biology under Robert Glen and Chris Bakal. He is co-founder and CTO of Phenomic AI, where he led development of single-cell RNA sequencing datasets for solid tumors and contributed to identifying drug targets now advancing in clinical development.
OKOren Kraus
Oren KrausCo-founderOren Kraus completed a BASc and MASc in mechanical engineering at the University of Toronto, where he later earned a PhD under Brendan Frey studying deep learning applications to microscopy image analysis. He co-founded Phenomic AI based on this research, and previously led machine learning teams at ProteinQure and Recursion.

Investors · 9

AV8 Ventureslisted by AV8 VenturesPalo Alto · $500K – $10M

How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

CTI Life Sciences Fund L.P.listed by CTI Life Sciences Fund L.P.Montréal

How we know: CTI Life Sciences Fund L.P.'s portfolio page · Not right? Tell us

Garage Capitallisted by Garage CapitalWaterloo

How we know: the VCSheet dataset · Not right? Tell us

Hemi Ventures, Llclisted by Hemi Ventures, LlcPalo Alto · $250K – $500Kvia Amy Gu · inferred

How we know: Hemi Ventures, Llc's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Toronto Innovation Acceleration Partnerslisted by Toronto Innovation Acceleration PartnersToronto
Hike VenturesreportedSan Francisco · $1M – $5M

How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Inovia CapitalreportedMontreal · $250K – $8M

How we know: a partner's Signal profile · Not right? Tell us

Radical VenturesreportedToronto · $1M – $25M

How we know: funding news · Not right? Tell us

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Related companies · 5

PhinomicsPhinomics is a cancer drug discovery platform that captures extrachromosomal circular DNA (the "Circulome") at high resolution from matched tumor and normal patient samples, integrating it with DNA, RNA, epigenetics, and proteomics into a multi-omic knowledge graph. It applies explainable AI to this data to identify novel therapeutic targets, resistance mechanisms, and patient stratification biomarkers for oncology therapeutics development.
Predictive OncologyPredictive Oncology develops drug discovery solutions for biopharma companies that combine artificial intelligence with a proprietary biobank of over 150,000 tumor samples to accelerate oncology drug development and improve therapeutic outcomes for cancer patients.
Genomics PlcGenomics builds a genotype-phenotype database and genetic risk-prediction tools used to support pharmaceutical drug discovery and clinical trials, as well as population health management and clinical decision support for healthcare providers. It serves life sciences companies and healthcare systems through its Life Sciences and Health & Wellness divisions.
TagomicsTagomics develops multimodal technologies for precision medicine and next-generation diagnostics. The company is based in Cambridge and focuses on improving patient outcomes through advanced diagnostic technologies.
Nomic BioNomic offers an end-to-end protein profiling service built on its nELISA technology, quantifying up to 1000 informative proteins with absolute quantification for research studies. It targets researchers doing proteomics work, aiming for high-throughput, low-cost profiling in the biotech and life sciences market.

Companies working in the same space as Phenomic AI.

In the news

Biotech startup Phenomic AI raises $7.97 million CAD to identify promising cancer drugs | BetaKitbetakit.com · Oct 2020

Frequently asked questions

What does Phenomic AI do?
Phenomic AI is a biotech company developing therapies for solid tumors using a machine-learning-powered transcriptomics platform that analyzes single-cell RNA data to identify drug targets and understand tumor biology. The company develops antibody-based therapies informed by its analysis of cell-cell interactions in tumor microenvironments, with current programs targeting stromal and immune components of difficult-to-treat cancers.
Who founded Phenomic AI?
Phenomic AI was founded by Sam Cooper, Oren Kraus in 2017.
Who are Phenomic AI's investors?
Phenomic AI's investors include Cantos Ventures, AV8 Ventures, CTI Life Sciences Fund L.P., Garage Capital, Hemi Ventures, Llc, Toronto Innovation Acceleration Partners, Hike Ventures, Inovia Capital and 1 more.
Where is Phenomic AI headquartered?
Phenomic AI is headquartered in Toronto, CA.